2024
International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma
Binkley M, Flerlage J, Savage K, Akhtar S, Steiner R, Zhang X, Dickinson M, Prica A, Major A, Hendrickson P, Hopkins D, Ng A, Casulo C, Baron J, Roberts K, Al Kendi J, Balogh A, Ricardi U, Torka P, Specht L, De Silva R, Pickard K, Blazin L, Henry M, Smith C, Halperin D, Brady J, Brennan B, Senchenko M, Reeves M, Hoppe B, Terezakis S, Talaulikar D, Picardi M, Kirova Y, Fergusson P, Hawkes E, Lee D, Doo N, Barraclough A, Cheah C, Ku M, Hamad N, Mutsando H, Gilbertson M, Marconi T, Viiala N, Maurer M, Eichenauer D, Hoppe R, Borchmann P, Fuchs M, Hartmann S, Eich H, Lo A, Skinnider B, Rauf M, Maghfoor I, Pinnix C, Milgrom S, Vega F, Alomari M, Collins G, Advani R, Metzger M, Wirth A, Tsang R, Smith S, Kelsey C, McKay P, Koenig J, Constine L, Sakthivel K, Plastaras J, Gao S, Al Rahbi N, Levis M, Sridhar A, Shah N, Osborne W, Chang I, Miall F, Mikhaeel G, Penn A, Volchkov E, Della Pepa R, Northend M, Opat S, Salvaris R, Tedjaseputra A, Palese M, Shankar A, Natkunam Y, Kelly K. International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma. Journal Of Clinical Oncology 2024, 42: 2271-2280. PMID: 38531001, DOI: 10.1200/jco.23.01655.Peer-Reviewed Original ResearchNodular lymphocyte-predominant Hodgkin lymphomaProgression-free survivalLymphocyte-predominant Hodgkin lymphomaInternational Prognostic ScoreImmunoarchitectural patternsOverall survivalHodgkin lymphomaPrognostic scoreSplenic involvementAssociated with worse progression-free survivalAssociated with progression-free survivalDe-escalation of therapyMedian follow-upAge of patientsProspective clinical trialHigh-risk patientsStage III-IVClinical risk factorsRisk of transformationStage I to IIB symptomsAdult patientsIII-IVActive surveillanceRare cancersO 09 Radiotherapy utilization and outcomes from a contemporary study of brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin lymphoma
Hoppe B, Castellino S, Pei Q, Charpentier A, Mailhot-Vega R, Roberts K, Parikh R, Flampouri S, Kelly K, Hodgson D. O 09 Radiotherapy utilization and outcomes from a contemporary study of brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin lymphoma. International Journal Of Particle Therapy 2024, 11: 100032. DOI: 10.1016/j.ijpt.2024.100032.Peer-Reviewed Original ResearchLate Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children
Lo A, Liu A, Liu Q, Yasui Y, Castellino S, Kelly K, Hererra A, Friedberg J, Friedman D, Schwartz C, Pei Q, Kessel S, Bergeron-Gravel S, Dama H, Roberts K, Constine L, Hodgson D. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children. JAMA Network Open 2024, 7: e2351062. PMID: 38241048, PMCID: PMC10799264, DOI: 10.1001/jamanetworkopen.2023.51062.Peer-Reviewed Original ResearchConceptsCardiac toxic effectsMediastinal RTHodgkin lymphomaRadiation therapyCumulative incidenceCardiac diseaseDoxorubicin doseCohort studyClinical trialsMedian mean heart doseChildren's Oncology Group clinical trialStudy populationHigh-risk HLMean heart dosePlanned cumulative doseRadiation therapy useIncidence of cardiac diseaseCumulative doxorubicin doseRisks associated with treatmentNorth American trialsGroup clinical trialFollow-up guidelinesStandard treatment groupToxic effectsMaintained long term
2020
Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG
Binkley M, Rauf M, Milgrom S, Pinnix C, Tsang R, Dickinson M, Ng A, Roberts K, Gao S, Balogh A, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras J, Wright C, Kelsey C, Brady J, Mikhaeel N, Hoppe B, Terezakis S, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig J, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine L, Eich H, Wirth A, Hoppe R. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood 2020, 135: 2365-2374. PMID: 32211877, DOI: 10.1182/blood.2019003877.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHodgkin DiseaseHumansKaplan-Meier EstimateLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm StagingNeoplasms, Radiation-InducedNeoplasms, Second PrimaryPositron Emission Tomography Computed TomographyProgression-Free SurvivalProportional Hazards ModelsRecurrenceRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeYoung AdultConceptsNodular lymphocyte-predominant Hodgkin lymphomaProgression-free survivalOverall survivalImmunoarchitectural patternsAssociated with worse progression-free survivalFive-year PFSLymphocyte-predominant Hodgkin lymphomaProgression-free survival ratesStudy of adult patientsSingle-agent rituximabLarge-cell transformationStage I diseaseMedian follow-upMulticenter retrospective studyMulti-institutional studyHodgkin lymphomaI diseaseRT cohortHistological variantsMedian agePrimary managementRetrospective studyRituximabAdult patientsRadiotherapy